Christopher Pieczonka, MD, director of clinical research, Crouse Health, discusses phase 2 data for the novel oral cytoskeletal disruptor sabizabulin (VERU-111) in metastatic castration-resistant prostate cancer (mCRPC) presented during the 2021 ASCO Annual Meeting (J Clin Oncol 39, 2021 [suppl 15; abstr 5056]. doi:10.1200/JCO.2021.39.15_suppl.5056). He also discusses toxicity differences between VERU-111 and docetaxel.
According to Pieczonka, additional phase 2 data for VERU-111 will be shared in September at the upcoming 2021 ESMO Annual Meeting. A phase 3 trial (NCT04844749) of VERU-111 in mCRPC has already been launched.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.